Coiled-coil-helix-coiled-coil-helix domain-containing 2 inhibits apoptosis of Parkinson’ s disease SH-SY5Y cells by promoting mitochondrial autophagy

doi:10.12307/2025.098

Abstract

Abstract: BACKGROUND: Whether coiled-coil-helix-coiled-coil-helix domain-containing 2 (CHCHD2) can regulate the neuroprotective role of PINK1/Parkin-mediated mitochondrial autophagy in Parkinson’s disease remains unknown.
OBJECTIVE: To explore the role and mechanisms of CHCHD2 in the 6-hydroxydopamine-induced Parkinson’s disease cell model in mediating the PINK1/Parkin signaling pathway and its involvement in mitochondrial autophagy.
METHODS: Utilizing recombinant plasmid transfection technology to overexpress or knockdown CHCHD2, SH-SY5Y cells were constructed with a Parkinson’s disease model using 6-hydroxydopamine, and divided into control group, model group, overexpression negative control+6-hydroxydopamine group, knockdown negative control+6-hydroxydopamine group, overexpression CHCHD2+6-hydroxydopamine group, and knockdown CHCHD2+6-hydroxydopamine group. Western blot assay and RT-qPCR were used to detect CHCHD2 expression. Western blot assay was utilized to detect the protein expression of LC3I/II, p62, MFN1, COXIV, DRP1, PINK1, Parkin, TIM23, Bax, Bcl-2, and cleaved-caspase 3. CCK-8 assay, JC-1, and reactive oxygen species assay kits were used to measure cell viability, mitochondrial membrane potential, and reactive oxygen levels. Monodansylcadaverine staining was used to observe cell autophagy. Transmission electron microscopy was used to observe autophagolysosomes.
RESULTS AND CONCLUSION: (1) Compared with the control group, cell activity, mitochondrial membrane potential, and the protein expression levels of CHCHD2, PINK1, and Parkin were decreased, and the levels of reactive oxygen species, apoptosis, and LC3I/II and p62 proteins were increased (P < 0.05), and the presence of autophagic lysosomes was observed in the model group. (2) Compared with the model group, overexpression of CHCHD2 could reduce the level of cellular reactive oxygen species, increase the mitochondrial membrane potential, and the expression levels of PINK1, Parkin, and MFN1 proteins, and observed an increase in mitochondrial autolysosomes, and the knockdown of CHCHD2 had the opposite effect with the increase of COXIV, TIM23 and p-DRP1 protein expression (P < 0.05). (3) Compared with the model group, overexpression of CHCHD2 reduced apoptosis, up-regulated Bcl-2, and down-regulated the expression of Bax and cleaved-caspase3 proteins, while knockdown of CHCHD2 had the opposite effect (P < 0.05). (4) The results suggest that CHCHD2 can play a neuroprotective role by promoting PINK1/Parkin-mediated mitochondrial autophagy, improving mitochondrial function, and alleviating apoptosis in 6-hydroxydopamine-induced Parkinson’s disease cell models.

Key words: Parkinson’s disease, coiled-coil-helix-coiled-coil-helix domain-containing 2, PINK1, Parkin, mitochondrial autophagy, mitochondrial function, cell apoptosis, 6-hydroxydopamine, SH-SY5Y cell

CLC Number:

Zhu Liuhui, Zhang Xinyue, Zhu Zhouhai, Yang Xinglong, Guan Ying, Liu Bin. Coiled-coil-helix-coiled-coil-helix domain-containing 2 inhibits apoptosis of Parkinson’ s disease SH-SY5Y cells by promoting mitochondrial autophagy[J]. Chinese Journal of Tissue Engineering Research, 2025, 29(25): 5403-5413.

Figures/Tables 5

References

[1] YE H, ROBAK LA, YU M, et al. Genetics and Pathogenesis of Parkinson’s Syndrome. Annu Rev Pathol. 2023;18:95-121.
[2] BHIDAYASIRI R, KALIA LV, BLOEM BR. Tackling Parkinson’s Disease as a Global Challenge. J Parkinsons Dis. 2023;13(8):1277-1280.
[3] KWON DK, KWATRA M, WANG J, et al. Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies. Cells. 2022;11(23):3736.
[4] MALPARTIDA AB, WILLIAMSON M, NARENDRA DP, et al. Mitochondrial Dysfunction and Mitophagy in Parkinson’s Disease: From Mechanism to Therapy. Trends Biochem Sci. 2021;46(4):329-343.
[5] FUNAYAMA M, OHE K, AMO T, et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson’s disease: a genome-wide linkage and sequencing study. Lancet Neurol. 2015;14(3):274-282.
[6] SHI CH, MAO CY, ZHANG SY, et al. CHCHD2 gene mutations in familial and sporadic Parkinson’s disease. Neurobiol Aging. 2016;38: 217.e9-217.e13.
[7] YANG N, ZHAO Y, LIU Z, et al. Systematically analyzing rare variants of autosomal-dominant genes for sporadic Parkinson’s disease in a Chinese cohort. Neurobiol Aging. 2019;76:215.e1-215.e7.
[8] JANSEN IE, BRAS JM, LESAGE S, et al. CHCHD2 and Parkinson’s disease. Lancet Neurol. 2015;14(7):678-679.
[9] KOSCHMIDDER E, WEISSBACH A, BRÜGGEMANN N, et al. A nonsense mutation in CHCHD2 in a patient with Parkinson disease. Neurology. 2016;86(6):577-579.
[10] IKEDA A, MATSUSHIMA T, DAIDA K, et al. A novel mutation of CHCHD2 p.R8H in a sporadic case of Parkinson’s disease. Parkinsonism Relat Disord. 2017;34:66-68.
[11] LEE RG, SEDGHI M, SALARI M, et al. Early-onset Parkinson disease caused by a mutation in CHCHD2 and mitochondrial dysfunction. Neurol Genet. 2018;4(5):e276.
[12] ZHOU W, MA D, TAN EK. Mitochondrial CHCHD2 and CHCHD10: Roles in Neurological Diseases and Therapeutic Implications. Neuroscientist. 2020;26(2):170-184.
[13] ZHOU W, MA D, SUN AX, et al. PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction. Hum Mol Genet. 2019;28(7):1100-1116.
[14] ARAS S, BAI M, LEE I, et al. MNRR1 (formerly CHCHD2) is a bi-organellar regulator of mitochondrial metabolism. Mitochondrion. 2015;20:43-51.
[15] LU Y, LI Z, ZHANG S, et al. Cellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation. Theranostics. 2023;13(2):736-766.
[16] MA KY, FOKKENS MR, REGGIORI F, et al. Parkinson’s disease-associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy. Transl Neurodegener. 2021; 10(1):19.
[17] MAGALHÃES JD, CARDOSO SM. Mitochondrial signaling on innate immunity activation in Parkinson disease. Curr Opin Neurobiol. 2023; 78:102664.
[18] XU Y, ZHI F, MAO J, et al. δ-opioid receptor activation protects against Parkinson’s disease-related mitochondrial dysfunction by enhancing PINK1/Parkin-dependent mitophagy. Aging (Albany NY). 2020;12(24):25035-25059.
[19] GLINKA Y, GASSEN M, YOUDIM MB. Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl. 1997;50:55-66.
[20] LIN CY, TSAI CW. PINK1/parkin-mediated mitophagy pathway is related to neuroprotection by carnosic acid in SH-SY5Y cells. Food Chem Toxicol. 2019;125:430-437.
[21] DI RITA A, D’ACUNZO P, SIMULA L, et al. AMBRA1-Mediated Mitophagy Counteracts Oxidative Stress and Apoptosis Induced by Neurotoxicity in Human Neuroblastoma SH-SY5Y Cells. Front Cell Neurosci. 2018;12:92.
[22] WEI L, DING L, MO MS, et al. Wnt3a protects SH-SY5Y cells against 6-hydroxydopamine toxicity by restoration of mitochondria function. Transl Neurodegener. 2015;4:11.
[23] YIN X, XIA J, SUN Y, et al. CHCHD2 is a potential prognostic factor for NSCLC and is associated with HIF-1a expression. BMC Pulm Med. 2020;20(1):40.
[24] WEI JP, WEN W, DAI Y, et al. Drinking water temperature affects cognitive function and progression of Alzheimer’s disease in a mouse model. Acta Pharmacol Sin. 2021;42(1):45-54.
[25] XIE L, GU Q, WU X, et al. Activation of LXRs Reduces Oxysterol Lipotoxicity in RPE Cells by Promoting Mitochondrial Function. Nutrients. 2022;14(12):2473.
[26] WEN S, WANG L, ZHANG C, et al. PINK1/Parkin-mediated mitophagy modulates cadmium-induced apoptosis in rat cerebral cortical neurons. Ecotoxicol Environ Saf. 2022;244:114052.
[27] KINET R, DEHAY B. Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson’s Disease. Cells. 2023;12(4):621.
[28] SOOKHAKLARI R, GERAMIZADEH B, ABKAR M, et al. The neuroprotective effect of BSA-based nanocurcumin against 6-OHDA-induced cell death in SH-SY5Y cells. Avicenna J Phytomed. 2019;9(2):92-100.
[29] ZHANG HY, JIANG YC, LI JR, et al. Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson’s disease. Neural Regen Res. 2023;18(5):1099-1106.
[30] IKEDA A, IMAI Y, HATTORI N. Neurodegeneration-associated mitochondrial proteins, CHCHD2 and CHCHD10-what distinguishes the two? Front Cell Dev Biol. 2022;10:996061.
[31] MENG H, YAMASHITA C, SHIBA-FUKUSHIMA K, et al. Loss of Parkinson’s disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nat Commun. 2017;8:15500.
[32] LI J, YANG D, LI Z, et al. PINK1/Parkin-mediated mitophagy in neurodegenerative diseases. Ageing Res Rev. 2023;84:101817.
[33] WANG S, LONG H, HOU L, et al. The mitophagy pathway and its implications in human diseases. Signal Transduct Target Ther. 2023; 8(1):304.
[34] JIANG Y, KRANTZ S, QIN X, et al. Caveolin-1 controls mitochondrial damage and ROS production by regulating fission - fusion dynamics and mitophagy. Redox Biol. 2022;52:102304.
[35] JI W, REN Y, WEI X, et al. Ischemic stroke protected by ISO-1 inhibition of apoptosis via mitochondrial pathway. Sci Rep. 2023;13(1):2788.
[36] AKABANE S, WATANABE K, KOSAKO H, et al. TIM23 facilitates PINK1 activation by safeguarding against OMA1-mediated degradation in damaged mitochondria. Cell Rep. 2023;42(5):112454.
[37] YAPA NMB, LISNYAK V, RELJIC B, et al. Mitochondrial dynamics in health and disease. FEBS Lett. 2021;595(8):1184-1204.
[38] JIANG T, WANG Y, WANG X, et al. CHCHD2 and CHCHD10: Future therapeutic targets in cognitive disorder and motor neuron disorder. Front Neurosci. 2022;16:988265.
[39] ZHANG HT, MI L, WANG T, et al. PINK1/Parkin-mediated mitophagy play a protective role in manganese induced apoptosis in SH-SY5Y cells. Toxicol In Vitro. 2016;34:212-219.
[40] GANGULY U, BANERJEE A, CHAKRABARTI SS, et al. Interaction of α-synuclein and Parkin in iron toxicity on SH-SY5Y cells: implications in the pathogenesis of Parkinson’s disease. Biochem J. 2020;477(6): 1109-1122.